



Empacoza plus
Pharmaceutical
Product Details:
- Active: Empagliflozin+Linagliptin
- Pack of 30 tablet
- Form: Tablet
- Concentration: 10/5mg , 25/5mg
- Speciality: All Specialities, Endocrinology & Metabolic, Cardiovascular
Brand Name: Empacoza Plus.
Composition:
Each Empacoza plus 10/5 mg tablet contains:
empagliflozin ........................................................ 10 mg
linagliptin ………………………………………………………. 5 mg
Each Empacoza 25/5 mg tablet contains:
empagliflozin ........................................................ 25 mg
Linagliptin ……………………………………………………. 5 mg
Therapeutic Indications
○ to improve glycaemic control when metformin and/or sulphonylurea (SU) and one of the monocomponents of ُEmpacoza Plus do not provide adequate glycaemic control
Dosage and Administration:
Warnings and precautions:
Undesirable Effects:
Contraindications:
Pharmacological Properties:
Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies, for the management of type 2 diabetes mellitus
Linagliptin is an inhibitor of DPP-4 an enzyme which is involved in the inactivation of the incretin
hormones GLP-1 and GIP (glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide).
These hormones are rapidly degraded by the enzyme DPP-4. Both incretin hormones are involved in the physiological regulation of glucose homeostasis.
Packaging:
Empacoza plus 10/5 mg Tablets: Box containing 3 blisters of 10 tablets each.
Empacoza plus 25/5 mg Tablets: Box containing 3 blisters of 10 tablets each.
36 Al Sheikh Mohammed Al Nadi St., Off Mostafa El Nahaas St. 6th District. Nasr City, Cairo, Egypt.